
Elutia Investor Relations Material
Latest events

Q1 2025
Elutia
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Elutia Inc
Access all reports
Elutia Inc., formerly known as Aziyo Biologics, Inc., is a commercial-stage company that focuses on developing and commercializing drug-eluting biomatrix technology to improve surgical outcomes. This technology is applied in products such as the CanGaroo Envelope, which is used to stabilize implantable cardiac devices like pacemakers and defibrillators, and SimpliDerm Acellular Dermal Matrix, which is utilized primarily in breast reconstruction following mastectomy. Elutia's mission revolves around humanizing medicine to ensure patients can thrive without the compromise, addressing the challenges associated with medical device implant failures and post-surgical complications. By integrating drug-eluting biologic technology with natural biologic material and extended antibiotic release, Elutia aims to optimize device implantation and soft tissue reconstruction, ensuring implant stability and promoting wound healing. Elutia Inc. is headquartered in Silver Spring, Maryland, and its shares are listed on the NASDAQ.
Key slides for Elutia Inc


Q4 2024
Elutia Inc


Q4 2024
Elutia Inc
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
ELUT
Country
🇺🇸 United States